• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

CMP Pharma Announces FDA-Approval on Atorvastatin Liquid Suspension


Atorvaliq indicated for the treatment of high cholesterol.

Cholesterol plaque in artery with Human heart anatomy. 3d illustration. Image Credit: Adobe Stock Images/Rasi

Image Credit: Adobe Stock Images/Rasi

CMP Pharma, Inc. revealed that the FDA has officially approved Atorvaliq (atorvastatin calcium), and is now available. Manufactured for the treatment of high cholesterol and a number of risk factors for heart disease and stroke, the medication is a liquid oral suspension approved for patients 10 years of age and older.

"Atorvaliq is intended for a subset of the patient population that needs atorvastatin but has dysphagia or difficulty swallowing tablets. The availability of Atorvaliq gives healthcare providers and appropriate patients a convenient, safe, and FDA-approved liquid formulation," said Gerald Sakowski, CEO of CMP Pharma, Inc.

Reference: CMP Pharma, Inc Announces that Atorvaliq®, the First and Only FDA-approved Liquid Suspension of Atorvastatin is Now Available. PR Newswire. June 23, 2023. Accessed June 26, 2023. https://www.prnewswire.com/news-releases/cmp-pharma-inc-announces-that-atorvaliq-the-first-and-only-fda-approved-liquid-suspension-of-atorvastatin-is-now-available-301858707.html

Recent Videos
Related Content